H5N1 VLP vaccine: Phase I start

Next month, not-for-profit Infectious Disease Research Institute (IDRI) (Seattle, Wash.) will begin a U.S. Phase I trial to compare 2 intradermal and intramuscular injections of 20 µg H5N1 VLP vaccin...